Nanjing Pharmaceutical Group Company Limited (SHA:600713)
China · Delayed Price · Currency is CNY 6.40
+0.43 (7.20%)
Apr 15, 2026, 3:00 PM CST
SHA:600713 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 624.83 | 570.63 | 577.83 | 595.67 | 505.18 |
Depreciation & Amortization | 274.26 | 251.42 | 270.4 | 260.47 | 241.48 |
Other Amortization | 28.62 | 34.05 | 18.34 | 16.1 | 17.44 |
Loss (Gain) From Sale of Assets | -293.31 | -3.85 | -1.75 | -23.79 | -60.54 |
Asset Writedown & Restructuring Costs | 25.11 | - | - | - | - |
Loss (Gain) From Sale of Investments | -4.79 | -4.02 | -8.58 | -2.88 | -7.57 |
Stock-Based Compensation | 15.1 | 7.93 | 17.59 | 16.56 | - |
Provision & Write-off of Bad Debts | 185.37 | 26.84 | -16.06 | 75.09 | 11.48 |
Other Operating Activities | 516.57 | 532.13 | 518.03 | 485.02 | 490.68 |
Change in Accounts Receivable | -1,584 | 454.05 | 3,807 | -4,990 | -1,360 |
Change in Inventory | -617.7 | -502.37 | -13.45 | -1,271 | -460.58 |
Change in Accounts Payable | 947.27 | 790.19 | -3,255 | 4,186 | 1,321 |
Change in Other Net Operating Assets | - | - | - | 0.98 | - |
Operating Cash Flow | 91.81 | 2,136 | 1,906 | -682.31 | 695.33 |
Operating Cash Flow Growth | -95.70% | 12.03% | - | - | - |
Capital Expenditures | -251.37 | -544.76 | -158.22 | -155.28 | -306.54 |
Sale of Property, Plant & Equipment | 269.1 | 7.09 | 6.6 | 93.31 | 37.89 |
Cash Acquisitions | - | - | -0 | - | -2 |
Divestitures | - | - | - | - | 0.2 |
Investment in Securities | -219.9 | -27.6 | -23.95 | 0.17 | 42.73 |
Other Investing Activities | 6.46 | 3.34 | 2.4 | 2.53 | 3.2 |
Investing Cash Flow | -195.7 | -561.93 | -173.18 | -59.26 | -224.52 |
Long-Term Debt Issued | 22,036 | 21,102 | 27,957 | 22,833 | 29,058 |
Total Debt Issued | 22,036 | 21,102 | 27,957 | 22,833 | 29,058 |
Long-Term Debt Repaid | -21,779 | -21,396 | -28,535 | -22,757 | -28,065 |
Total Debt Repaid | -21,779 | -21,396 | -28,535 | -22,757 | -28,065 |
Net Debt Issued (Repaid) | 256.19 | -293.92 | -578.53 | 75.14 | 992.89 |
Issuance of Common Stock | 71.6 | - | - | 1,030 | - |
Repurchase of Common Stock | - | -2.12 | -0.17 | - | - |
Common Dividends Paid | -617.61 | -504.83 | -587.94 | -482.89 | -934.87 |
Other Financing Activities | -141.1 | -38.91 | 9.87 | -155.37 | -27.17 |
Financing Cash Flow | -430.93 | -839.77 | -1,157 | 466.62 | 30.85 |
Net Cash Flow | -534.83 | 734.07 | 576.46 | -274.95 | 501.66 |
Free Cash Flow | -159.57 | 1,591 | 1,748 | -837.59 | 388.79 |
Free Cash Flow Growth | - | -8.99% | - | - | - |
Free Cash Flow Margin | -0.29% | 2.96% | 3.26% | -1.67% | 0.86% |
Free Cash Flow Per Share | -0.11 | 1.22 | 1.35 | -0.67 | 0.37 |
Cash Income Tax Paid | - | 1,007 | 961.27 | 1,031 | 742.15 |
Levered Free Cash Flow | 3,746 | 1,456 | 3,354 | -2,793 | -338.73 |
Unlevered Free Cash Flow | 3,940 | 1,765 | 3,681 | -2,585 | -64.35 |
Change in Working Capital | -1,280 | 720.64 | 530.61 | -2,105 | -502.81 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.